Compassionate access program offers continued treatment for immune deficiency
NCT ID NCT06955793
First seen Jul 15, 2026 · Last updated Jul 16, 2026 · Updated 1 time
Summary
This expanded access program provides TAK-881, a subcutaneous immunoglobulin treatment, to people with primary immunodeficiency diseases (PIDD) who completed a prior study and continue to benefit from the therapy. Participants receive regular infusions under the skin using a special needle set. The program aims to maintain access until the treatment becomes commercially available or the participant no longer benefits.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- TAK-881 (immune globulin subcutaneous with recombinant human hyaluronidase)
- What this could lead to
- If successful, this program offers continued access to a potentially effective treatment for people with primary immunodeficiency diseases.
- What could go wrong
- This is an expanded access program, not a controlled trial, so results are observational and may not prove safety or effectiveness broadly. Individual responses may vary.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PRIMARY IMMUNODEFICIENCY DISEASES (PIDD) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••